Monte Rosa Therapeutics, Inc.
GLUE
$16.86
$1.459.41%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -120.26% | -126.22% | 248.92% | 156.32% | 21.28% |
| Total Depreciation and Amortization | 0.63% | 2.53% | 3.40% | -4.48% | 18.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -8.58% | -1.19% | 10.30% | 25.16% | -18.20% |
| Change in Net Operating Assets | 523.30% | 70.90% | -189.95% | 4,610.53% | 16.89% |
| Cash from Operations | 389.25% | 23.68% | -135.29% | 714.09% | 24.39% |
| Capital Expenditure | 61.59% | -6.81% | -767.21% | 54.14% | 80.27% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 43.56% | 127.39% | -221.17% | -180.51% | 164.51% |
| Cash from Investing | 50.60% | 125.27% | -224.41% | -181.85% | 161.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -4.66% | 2,507.14% | -97.70% | 3,953.33% | -99.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -100.00% |
| Cash from Financing | -4.66% | 2,507.14% | -97.70% | 3,953.33% | -99.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,638.19% | 93.80% | -247.72% | 488.16% | 84.33% |